🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Early Stage Triple-Negative Breast Carcinoma

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) NCT07743190Phase 22 sites📍 Syracuse📍 Charleston Medical University of South Carolina · Tests: Carboplatin, Paclitaxcel, Pembrolizumab PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC NCT06245889Phase 22 sites📍 Baltimore📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide Pucotenlimab and Anlotinib in Combination With Chemotherapy NCT07896668Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: LP I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras… Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer NCT06606730Phase 32 sites📍 Brussels📍 Villejuif UNICANCER · Tests: Pembrolizumab, Deescalation Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies NCT07211178n/a16 sites📍 Birmingham📍 Whittier📍 Weston Tempus AI · Tests: There are no interventions in this observational study. Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy NCT06313463Phase 31 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Carrellizumab + Capecitabine, Placebo + Capecitabine A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer NCT06508216Phase 1, Phase 21 site📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Dato-DXd, Durvalumab Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab NCT05877859n/a1 site📍 Atlanta Emory University Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer NCT04959474NA1 site📍 Philadelphia Thomas Jefferson University · Tests: Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer NCT05929768Phase 3963 sites📍 Birmingham📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial NCT07407920Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Biospecimen Collection, Hormone Therapy, Pembrolizumab, Pertuzumab, Trastuzumab Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC NCT07016399Phase 21 site📍 Nashville Vandana Abramson · Tests: Biospecimen Collection, Breast Biopsy Procedure, Carboplatin, Cyclophosphamide, Darolutamide Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer NCT07017673Phase 24 sites📍 Los Angeles📍 Los Angeles📍 Pasadena Cedars-Sinai Medical Center · Tests: Ivonescimab, Carboplatin, Docetaxel Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer NCT05020860Phase 22 sites📍 Houston📍 Houston Baylor Breast Care Center · Tests: Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer NCT06768931Phase 25 sites📍 Lanzhou📍 Dongguan📍 Guangzhou Sun Yat-sen University · Tests: Biolosion (oral probiotic compound preparation) Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC NCT06817525Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1), 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1) Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635Phase 217 sites📍 Santa Monica📍 Skokie📍 Billings Merck Sharp & Dohme LLC · Tests: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride FMD and Neoadjuvant Chemo-immunotherapy in TNBC NCT07378306Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Fasting-mimicking diet, Chemotherapy, Toripalimab TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC NCT07074106Phase 25 sites📍 Brasília📍 Curitiba📍 Rio de Janeiro D'Or Institute for Research and Education · Tests: Carboplatin and a Taxane Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC NCT07216495NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Exercise CtDNA Based MRD Testing for NAC Monitoring in TNBC NCT06230185n/a14 sites📍 Tucson📍 Aurora📍 Washington D.C. Personalis Inc. A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer NCT07768436Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: CMF Regimen, Paclitaxel EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase NCT06894173n/a29 sites📍 Aviano📍 Ancona📍 Avellino Fondazione Policlinico Universitario Agostino Gemelli IRCCS DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer NCT05504707Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: HER2 - primed Dendritic cells, HER3 - primed Dendritic cells Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer NCT06324240Phase 14 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Ipilimumab, Pembrolizumab, Vaccine Therapy Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer NCT04768426Phase 21 site📍 Stanford Stanford University · Tests: Capecitabine A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC NCT07178171Phase 11 site📍 Xi'an Xijing Hospital · Tests: QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pirarubicin, Nab-paclitaxel, Carboplatin (AUC 5), Cyclophospham… Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK NCT06358573Phase 210 sites📍 Lyon📍 Aarau📍 Basel Swiss Cancer Institute · Tests: INT230-6, neoadjuvant immuno-chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy